OpGen (OPGN): Earnings growth forecast for next year

OpGen Corp (OPGN) - corporate logo

OpGen, Inc. (OPGN) develops molecular analysis systems to combat antibiotic resistance. Analyst 12-month EPS growth targets confirm a crisis, where 0.00 reflects the metric's baseline. The Unyvero IT platform integrated rapid tests with AI databases, but the company is currently liquidating assets due to the bankruptcy of its European divisions and the failure to commercialize its developments.

OPGN - OpGen Inc Projected earnings per share increase next year over the range 07/04/2022 - 08/31/2024

Metric breakdowns and analytics for opgen.com (OPGN)

- share price and consensus valuation forecast:
Stock Price OpGen Corp|OPGN - Average Forecast Price
- stock exchange capitalization data:
Market Capitalization OpGen|OPGN - Real Price to Acquire Entire Company
- book capitalization indicators:
Accounting Value per Share OpGen|OPGN - Total Net Assets|Market Capitalization to Book Value Ratio opgen.com|OPGN - Company Total Asset Base
- company liabilities and liquidity data:
Debt to Equity OpGen, Inc.|OPGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity OpGen|OPGN - Company Aggregate Debt|Debt to Book Capitalization Ratio OpGen|OPGN - Long-Term Debt Volume|Company Short-Term Debt OpGen|Quick Liquidity opgen.com
- earnings and market ratios statistics:
OPGN - Profit After Tax|Projected Future Earnings OpGen, Inc.|OPGN - Market Cap to Net Income Ratio|Forward P/E Multiple OpGen, Inc.|OPGN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OpGen|OPGN - Operating profit before amortization|Net earnings per share for the last 12 months OpGen|OPGN - Earnings per share for the trailing year|Quarterly EPS earnings growth opgen.com|OPGN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year OpGen, Inc.
- sales volume and revenue information:
OPGN - Company Sales Volume|Projected Sales Volume OpGen Corp|OPGN - Market Cap to Revenue|Forward Price-to-Revenue Multiple OpGen
General company analysis:OPGN, OpGen Corp
Core merchandise of OpGen

This indicator measures the dynamics of consensus earnings forecasts for the coming year, reflecting the amplitude of shifts in market expectations and the degree of transparency in corporate reporting. By analyzing the growth rate model for next year's earnings, an investor can assess volatility risks in demand for OpGen, Inc. (OPGN) molecular diagnostic systems and tests, where sharp fluctuations in the metric signal uncertainty regarding commercial prospects.

Competitor analysis

SMMT (Summit Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Moderna Therapeutics MRNA|Earnings growth forecast for next year PCVX|Expected earnings per share growth for next year tarsusrx.com TARS|CorMedix - Expected earnings per share growth for next year|Projected earnings per share increase next year MCRB (Seres Therapeutics Inc.)|Spero - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year SCYNEXIS, Inc. SCYX|an2therapeutics.com (ANTX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year PolyPid (PYPD)|Net earnings per share growth forecast for next year LakeShore Biopharma|Projected earnings per share growth rate for next year ITRM (Iterum Therapeutics, plc)|Net earnings per share growth forecast for next year BiomX Inc. (PHGE)|Consensus forecast of earnings per share growth for next year soligenix.com|Net earnings per share growth forecast for next year 60 Degrees Pharmaceuticals, Inc. SXTP|Oragenics Inc. (OGEN) - Expected net earnings per share growth next year